AbbVie and RemeGen’s bispecific goes pivotal
Chinese trials in first-line NSCLC and colorectal cancer are imminent.
Compass points the way towards its next readout
Progression-free and overall survival data from Companion-002 are due this quarter.
The relentless march of VEGF bispecifics
Two new pivotal Chinese first-line trials have started in lung cancer.
Pfizer mimics pumitamig in gastroesophageal cancers
The company will start a phase 2/3 trial of PF-08634404 in March.
Pumitamig pivotal trials come in pairs
Bristol will test the bispecific in two new lung indications.
Huabo goes pivotal with bispecific VEGF trap
The company takes a PD-L1 x VEGF asset into phase 3.
Instil’s bispecific dream is over
The company hands its PD-L1 x VEGF bispecific back to ImmuneOnco.
Henlius and Ottimo join the bispecific bundle
Two new PD-(L)1 x VEGF projects have entered the clinic.
SABCS 2025 – pumitamig replicates breast cancer findings
Global phase 2 data in TNBC look similar to earlier results in China.
